Skip to content

To evaluate the efficacy and safety of continuous glucose monitoring system in adults with diabetes mellitus (DM) in a randomized, self-controlled, multicenter clinical trial

To evaluate the efficacy and safety of continuous glucose monitoring system in adults with diabetes mellitus (DM) in a randomized, self-controlled, multicenter clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400088719
Enrollment
Unknown
Registered
2024-08-26
Start date
2024-08-31
Completion date
Unknown
Last updated
2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

CGM Wearing Group:None

Sponsors

The Central Hospital of Wuhan
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Be over 18 years of age; 2) Clinical diagnosis of diabetes; 3) Willing to worn equipment 15 days, and according to the requirements of the scheme for blood glucose values; 4) Agree to participate in this clinical trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) MRI is required during the trial; 2) Presence of adverse skin conditions (e.g., diffuse subcutaneous nodules, psoriasis, scars, etc.) in the area where the glucose sensor is implanted (abdomen); 3) Acute diabetic complications such as diabetic ketoacidosis (DKA), hyperglycemic hyperosmotic syndrome (HHS), etc.; 4) Coagulant function abnormality, abnormal judgment standard is: i. An activated partial thromboplastin time (APTT) greater than 1.5 times the upper limit of normal, or lower than the lower limit of normal; or Ii. The prothrombin time (PT) is higher than 1.5 times the upper limit of normal value, the lower limit or below normal. 5) Participated in other clinical trials within 1 month before screening, except the clinical trial sponsored by Weitai Medical Device (Hangzhou) Co., LTD.; 6) The researchers think that doesn't fit into the group.

Design outcomes

Primary

MeasureTime frame
The agreement with the reference value of 20/20% was evaluated by the agreement rate;The proportion of measurement points falling in the A+B region of the Clarke error grid analysis;The proportion of measurement points falling in the Consensus error grid was analyzed in the A+B region;Mean absolute relative error (MARD%);Safety evaluation indicators;

Secondary

MeasureTime frame
Alarm accuracy rate;Stability of sensor;Repeatability of sensor;The calibration function;Ease of use;Lifetime of sensor;Blood sugar levels or greater tendency for 3.9 L and 10 or less tendency, > 10 tendency when L/L, and the accuracy of the reference value of 15%, 40%; When the blood glucose concentration was less than 3.9mmol/L, the accuracy was 0.83mmol/L and 2.22mmol/L, respectively;

Countries

China

Contacts

Public ContactWang Zhongjing

The Central Hospital of Wuhan

doctorwangzj@163.com+86 130 0711 1056

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026